AURA

NASDAQ

Aura Biosciences Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2021

News25/Ratings11

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

News · 26 weeks30+17%

2025-10-262026-04-19

Mix1990d

Insider12(63%)
SEC Filings5(26%)
Other2(11%)

Latest news

25 items

3dSEC
SEC Form DEFA14A filed by Aura Biosciences Inc.
DEFA14A - Aura Biosciences, Inc. (0001501796) (Filer)
3dSEC
SEC Form DEF 14A filed by Aura Biosciences Inc.
DEF 14A - Aura Biosciences, Inc. (0001501796) (Filer)
7dINSIDER
SEC Form 4 filed by Kilroy Conor
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
24dSEC
SEC Form S-8 filed by Aura Biosciences Inc.
S-8 - Aura Biosciences, Inc. (0001501796) (Filer)
24dSEC
SEC Form 10-K filed by Aura Biosciences Inc.
10-K - Aura Biosciences, Inc. (0001501796) (Filer)
24dPR
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular Solid Tumor Indications, Beginning with Urologic Oncology BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. "2025 has been a year
24dSEC
Aura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
51dINSIDER
Officer De Los Pinos Elisabet was granted 166,000 shares, increasing direct ownership by 41% to 575,815 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
51dINSIDER
Officer Gibney Anthony S was granted 71,245 shares, increasing direct ownership by 34% to 278,178 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
51dINSIDER
Officer Kilroy Conor was granted 62,339 shares, increasing direct ownership by 37% to 229,573 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
51dINSIDER
Chief Technology Officer Plavsic Mark was granted 62,339 shares, increasing direct ownership by 34% to 243,736 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
51dINSIDER
Chief Medical Officer Hopkins Janet Jill was granted 89,056 shares, increasing direct ownership by 38% to 321,340 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
51dINSIDER
Senior Vice President, Finance Elazzouzi Amy was granted 44,528 shares, increasing direct ownership by 59% to 120,060 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
57dPR
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026. Fireside Chat at 9:10 a.m. ET. Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Fireside Chat at 3:40 p.m. ET. The Citizens Life Sciences Conference on Wednesday, March 11, 2026. Fireside Chat at 11:20 a.m. ET. The live webcasts of the fireside chats will be available
65dINSIDER
Officer Kilroy Conor sold $60,999 worth of shares (12,079 units at $5.05), decreasing direct ownership by 7% to 167,234 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
65dINSIDER
Chief Technology Officer Plavsic Mark sold $80,244 worth of shares (15,890 units at $5.05), decreasing direct ownership by 8% to 181,397 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
65dINSIDER
Chief Medical Officer Hopkins Janet Jill sold $103,229 worth of shares (20,401 units at $5.06), decreasing direct ownership by 8% to 232,284 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
65dINSIDER
Senior Vice President, Finance Elazzouzi Amy sold $43,258 worth of shares (8,549 units at $5.06), decreasing direct ownership by 10% to 75,532 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
65dINSIDER
Officer De Los Pinos Elisabet sold $241,099 worth of shares (47,648 units at $5.06), decreasing direct ownership by 10% to 409,815 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
93dINSIDER
Senior Vice President, Finance Elazzouzi Amy sold $7,684 worth of shares (1,581 units at $4.86), decreasing direct ownership by 2% to 84,081 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
93dINSIDER
Officer De Los Pinos Elisabet sold $82,270 worth of shares (16,928 units at $4.86), decreasing direct ownership by 4% to 457,463 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
148dANALYST
Evercore ISI resumed coverage on Aura Biosciences with a new price target
Evercore ISI resumed coverage of Aura Biosciences with a rating of Outperform and set a new price target of $13.00
150dPR
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference
BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:50 a.m. ET. The live webcast of the fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company's website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following t
154dPR
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa
157dINSIDER
Chief Medical Officer Hopkins Janet Jill sold $92,731 worth of shares (17,109 units at $5.42), decreasing direct ownership by 6% to 252,685 units (SEC Form 4)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)